Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

701. Glucose-insulin-potassium in cardiac surgery: a meta-analysis

Glucose-insulin-potassium in cardiac surgery: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

702. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials

Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

703. Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications

Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives This study aims to summarise the available evidence on insulin pumb treatment of diabetes mellitus. Authors' conclusions CSII represents a higher cost in diabetes type 1

2004 Health Technology Assessment (HTA) Database.

704. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes

Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Cote B, St-Hilaire C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Cote B, St-Hilaire C. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 04-07. 2004 Authors' objectives This report examines the safety, efficacy and cost-effectiveness of the insulin pump compared to multiple daily insulin injections for the treatment of type 1 diabetes, a chronic

2004 Health Technology Assessment (HTA) Database.

705. Insulin aspart: an evidence-based medicine review

Insulin aspart: an evidence-based medicine review Insulin aspart: an evidence-based medicine review Insulin aspart: an evidence-based medicine review Haycox A CRD summary Evidence on the efficacy, safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin, in diabetes mellitus, was reviewed. The review concluded that there is evidence to support the efficacy, tolerability and ease of administration of insulin aspart. However (...) , it is difficult to assess the reliability of this conclusion. Authors' objectives To review and evaluate the published evidence on the efficacy, safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI), in diabetes mellitus. Searching The Cochrane Library, BIOSIS Previews, EMBASE-DP and MEDLINE were searched; the search period was not reported. The search was restricted to publications in the English language. Study selection Study designs

2004 DARE.

706. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N CRD summary This review investigated the clinical effectiveness and cost-effectiveness of insulin treatment for diabetes, by comparing continuous subcutaneous insulin infusion (...) (from a pump) with multiple daily injections. It concluded that continuous infusion treatment resulted in a modest improvement in glycated haemoglobin levels in adults with type 1 diabetes. This was a well-conducted review and most of the conclusions are justified. Authors' objectives To assess the clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) using insulin pumps, compared with intensive treatment with multiple daily injections (MDI

2004 DARE.

707. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Warren E, Weatherley-Jones E, Chilcott J, Beverley C CRD summary This review concluded there was some evidence that insulin glargine was more effective than once-daily neutral protamine Hagedorn in reducing nocturnal (...) hypoglycaemia incidence, but there was no evidence of long-term glycaemic control improvement. The review methodology was poorly reported and the available data were limited, but the authors' cautious conclusions reflect the data presented and are likely to be reliable. Authors' objectives To assess the incremental clinical and cost-effectiveness of basal-bolus insulin glargine, a long-acting insulin analogue, compared with existing basal-bolus insulin treatments. Searching The following databases were

2004 DARE.

708. Use of metabolic markers to identify overweight individuals who are insulin resistant. (Abstract)

Use of metabolic markers to identify overweight individuals who are insulin resistant. Insulin resistance is more common in overweight individuals and is associated with increased risk for type 2 diabetes mellitus and cardiovascular disease. Given the current epidemic of obesity and the fact that lifestyle interventions, such as weight loss and exercise, decrease insulin resistance, a relatively simple means to identify overweight individuals who are insulin resistant would be clinically (...) useful.To evaluate the ability of metabolic markers associated with insulin resistance and increased risk for cardiovascular disease to identify the subset of overweight individuals who are insulin resistant.Cross-sectional study.General clinical research center.258 nondiabetic, overweight volunteers.Body mass index; fasting glucose, insulin, lipid and lipoprotein concentrations; and insulin-mediated glucose disposal as quantified by the steady-state plasma glucose concentration during the insulin

2003 Annals of Internal Medicine

709. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. (Abstract)

Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Several experimental investigations have emphasized the favorable effects of insulin-like growth factor I (IGF-I) on left ventricular remodeling, partly through its antiapoptotic effects. Cross-sectional clinical studies have reported that low serum IGF-I levels in patients with heart failure correlate with cachexia and severity

2003 Annals of Internal Medicine

710. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Full Text available with Trip Pro

Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Impaired glucose tolerance is common among obese adolescents, but the changes in insulin sensitivity and secretion that lead to this prediabetic state are unknown. We investigated whether altered partitioning of myocellular and abdominal fat relates to abnormalities in glucose homoeostasis in obese adolescents with prediabetes.We studied 14 (...) obese children with impaired glucose tolerance and 14 with normal glucose tolerance, of similar ages, sex distribution, and degree of obesity. Insulin sensitivity and secretion were assessed by the euglycaemic-hyperinsulinaemic clamp and the hyperglycaemic clamp. Intramyocellular lipid was assessed by proton nuclear magnetic resonance spectroscopy and abdominal fat distribution by magnetic resonance imaging.Peripheral glucose disposal was significantly lower in individuals with impaired than

2003 Lancet

711. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. (Abstract)

Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. Newer insulin therapies, including the concept of physiologic basal-prandial insulin and the availability of insulin analogues, are changing clinical diabetes care. The key to effective insulin therapy is an understanding of principles that, when implemented, can result in improved diabetes control.To systematically review the literature regarding insulin use in patients with type 1 and type 2 diabetes (...) mellitus (DM).A MEDLINE search was performed to identify all English-language articles of randomized controlled trials involving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003. Bibliographies and experts were used to identify additional studies.Studies were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 weeks long with at least 10 patients in each group

2003 JAMA

712. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. Full Text available with Trip Pro

Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. Understanding when to use insulin and how to apply the principles of physiologic insulin replacement using existing and new insulins is a key step to improving diabetes care. Insulin analogues and premixed insulins increase physicians' and patients' ability to lower hemoglobin A1C levels with fewer episodes of hypoglycemia. Earlier use of insulin and more aggressive dose escalation are important steps (...) in achieving treatment goals. This article discusses using bedtime insulin with oral agents, basal-prandial insulin strategies, and the new insulin analogues.

2003 JAMA

713. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. (Abstract)

Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Insulin-like growth factor-I (IGF-I) is a potent survival factor for motor neurons and is being investigated as possible therapeutic agent for amyotrophic lateral sclerosis. However, very little information is available on the components of the IGF-I system in this disease. Insulin-like growth factor binding proteins (IGFBPs) play an important part in regulating

2003 Lancet

714. Low nutrient intake and early growth for later insulin resistance in adolescents born preterm. (Abstract)

Low nutrient intake and early growth for later insulin resistance in adolescents born preterm. In animals, acceleration of neonatal growth is thought to increase the later propensity to insulin resistance and non-insulin-dependent diabetes, whereas slow growth as a consequence of undernutrition is thought to have a beneficial effect. To test this hypothesis in people, we measured fasting concentrations of 32-33 split proinsulin, a marker of insulin resistance, in adolescents born preterm who (...) , anthropometric, and socioeconomic factors.Our results suggest that relative undernutrition early in life in children born preterm may have beneficial effects on insulin resistance.

2003 Lancet Controlled trial quality: uncertain

715. Inhaled insulin in diabetes mellitus. (Abstract)

Inhaled insulin in diabetes mellitus. Insulin therapy often relies on multiple daily injections of insulin. However this is a considerable burden to many people with diabetes and adherence to such an insulin regimen can be difficult to maintain, hence compromising optimal glycaemic control. Also, short acting injected insulin is absorbed more slowly than insulin released by the normal pancreas in response to a meal. Inhaled insulin has the potential to reduce the number of injections to perhaps (...) one long-acting insulin per day, and provide a closer match to the natural state, by more rapid absorption from the lung.To compare the efficacy, adverse effects and patient acceptability of inhaled versus injected insulin.A sensitive search strategy for randomised controlled or cross-over trials was combined with key terms for inhaled insulins. Databases searched were: The Cochrane Library, MEDLINE, PubMed, EMBASE, Science Citation Index, BIOSIS, Web of Science Proceedings, National Research

2003 Cochrane

716. Guidance on the use of continuous subcutaneous insulin infusion for diabetes

Guidance on the use of continuous subcutaneous insulin infusion for diabetes Guidance on the use of continuous subcutaneous insulin infusion for diabetes Guidance on the use of continuous subcutaneous insulin infusion for diabetes National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence (...) . Guidance on the use of continuous subcutaneous insulin infusion for diabetes. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 57. 2003 Authors' objectives To provide guidance on the use of continuous subcutaneous insulin infusion for diabetes. Authors' conclusions Guidance: 1.1 Continuous subcutaneous insulin infusion (CSII or insulin pump therapy') is recommended as an option for people with type 1 diabetes provided that: multiple-dose insulin (MDI) therapy

2003 Health Technology Assessment (HTA) Database.

717. Insulin glargine: a long-acting insulin for diabetes mellitus

Insulin glargine: a long-acting insulin for diabetes mellitus Insulin glargine: a long-acting insulin for diabetes mellitus Insulin glargine: a long-acting insulin for diabetes mellitus Garces K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Garces K. Insulin glargine: a long-acting insulin for diabetes mellitus. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2003 Authors' objectives To summarize the available information on the use of insulin glargine (Lantus(TM), manufactured by Aventis Pharma) to treat patients over 17 years of age with type 1 or type 2 diabetes mellitus who require long-acting insulin control of hyperglycemia. Authors' conclusions Insulin glargine is a treatment option for patients with type 1 diabetes mellitus. The evidence supporting its use over NPH insulin is limited, so

2003 Health Technology Assessment (HTA) Database.

718. Pancreas transplant for insulin-dependent diabetes

Pancreas transplant for insulin-dependent diabetes Pancreas transplant for insulin-dependent diabetes Pancreas transplant for insulin-dependent diabetes Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Pancreas transplant for insulin-dependent diabetes. Bloomington MN (...) : Institute for Clinical Systems Improvement (ICSI) 2003 Authors' objectives This review aims to assess the available evidence on pancreas transplant for insulin-dependent diabetes. Authors' conclusions With respect to pancreas transplants, the ICSI Technology Assessment Committee finds the following: Nearly all uremic diabetics are candidates for a kidney transplant and most should also receive a pancreas either simultaneously (SPK) or sequentially (PAK). For those who have a living donor for a kidney

2003 Health Technology Assessment (HTA) Database.

719. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes

The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes Scuffham P, Carr L Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of continuous subcutaneous insulin infusion (CSII) was compared with multiple daily injections (MDI) for the treatment of diabetes. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study

2003 NHS Economic Evaluation Database.

720. Inhaled insulins (TCR)

Inhaled insulins (TCR) Inhaled insulins (TCR) Inhaled insulins (TCR) Halas C Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Halas C. Inhaled insulins (TCR) University HealthSystem Consortium (UHC). Drug Monograph. 2003 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals (...) comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Drug Delivery Systems; Insulin Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu AccessionNumber 32006001071 Date

2003 Health Technology Assessment (HTA) Database.